(NASDAQ: TSHA) Taysha Gene Therapies's forecast annual revenue growth rate of 148.41% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.68%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.13%.
Taysha Gene Therapies's revenue in 2026 is $7,471,000.On average, 15 Wall Street analysts forecast TSHA's revenue for 2026 to be $586,216,481, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $4,525,936,065. On average, 13 Wall Street analysts forecast TSHA's revenue for 2027 to be $10,647,587,874, with the lowest TSHA revenue forecast at $0, and the highest TSHA revenue forecast at $34,922,984,761.
In 2028, TSHA is forecast to generate $36,980,489,664 in revenue, with the lowest revenue forecast at $26,302,728,883 and the highest revenue forecast at $57,081,393,013.